These findings confirm that in patients with cardiac hypertrophy, ROS levels induce oxidative stress, leading to increased expression of NLRP3/IL-18, and some therapeutic agents associated with oxidative stress can reduce the expression of genes associated with cardiac hypertrophy. The gene discussed is IL18; the disease is cardiac hypertrophy.